Abstract
Maple Syrup Urine Disease (MSUD) is an autossomal recessive metabolic disorder caused by a deficiency of branched-chain α-keto acid dehydrogenase complex activity leading to accumulation of the branched-chain amino acids leucine, isoleucine and valine and their corresponding branched-chain α-keto acids. Affected patients usually present hypoglycemia, ketoacidosis, convulsions, poor feeding, coma, psychomotor delay and mental retardation. Considering that the pathophysiology of MSUD is still poorly understood, in this study we evaluated some parameters of oxidative stress, namely thiobarbituric acid-reactive substances (TBARS), total antioxidant reactivity (TAR) and total antioxidant status (TAS) in plasma from treated MSUD patients presenting high and low plasma leucine levels. We verified a significant increase of TBARS (lipid peroxidation) and a decrease of TAR (capacity to rapidly react with free radicals) in plasma from treated MSUD patients with low and with high plasma levels of leucine compared to the control group. It was also verified that TAS (quantity of tissue antioxidants) was not altered in plasma from treated MSUD patients with low and high blood leucine levels. Finally, we found no correlation between leucine, valine and isoleucine levels with the various parameters of oxidative stress. These results are indicative that increased lipid oxidative damage and decreased antioxidant defenses occur in plasma of MSUD patients and that the accumulating branched-chain amino acids are probably not directly associated to oxidative stress in this disorder.
Similar content being viewed by others
References
Altman DG (1991) Practical statistics for medical research. Chapman & Hall, London
Araújo PR, Wassermann GF, Tallini K, Furlanetto V, Vargas CR, Wannmacher CMD, Dutra-Filho CS, Wyse ATS, Wajner M (2001) Reduction of large neutral amino acid level in plasma and brain of hyperleucinemic rats. Neurochem Int 38:529–537
Barschak AG, Sitta A, Deon M, Oliveira MH, Haeser A, Dutra-Filho CS, Wajner M, Vargas CR (2006) Evidence that oxidative stress is increased in plasma from patients with Maple Syrup Urine Disease. Metab Brain Dis 21:279–286
Ben–Menachem E, Kyllerman R, Markleind S (2000) Superoxide dismutase and glutathione peroxidase function in progressive myoclonus epilepsies. Epilepsy Res 40:33–39
Bridi R, Araldi J, Sgarbi MB, Testa CG, Durigon K, Wajner M, Dutra-Filho CS (2003) Induction of oxidative stress in rat brain by the metabolites accumulating in maple syrup urine disease. Int J Dev Neurosci 21:327–332
Bridi R, Braun CA, Zorzi GK, Wannmacher CMD, Wajner M, Lissi EG, Dutra-Filho CS (2005a) Alpha-keto acids accumulating in maple syrup urine disease stimulate lipid peroxidation and reduce antioxidant defences in cerebral cortex from young rats. Metab Brain Dis 20:155–167
Bridi R, Latini A, Braum CA, Zorzi GK, Wajner M, Lissi E, Dutra-Filho CS (2005b) Evaluation of the mechanism involved in leucine-induced oxidative damage in cerebral córtex of young rats. Free Radic Res 39:71–79
Buege JA, Aust SD (1978) Microssomal lipid peroxidation. Methods Enzymol 52:302–309
Chuang DT, Shih VE (2001) Maple syrup urine disease (branched-chain ketoaciduria). In: Scriver CR, Beaudt AL, Sly WL, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1971–2005
Coitinho AS, de Mello CF, Lima TT, de Bastiani J, Fighera MR, Wajner M (2001) Pharmacological evidence that alpha-keto isovaleric acid induces convulsions through GABAergic and glutamatergic mechanisms in rats. Brain Res 894:68–73
Colome C, Sierra C, Vilaseca MA (2000) Congenital errors of metabolism: cause of oxidative stress? Med Clin 115:111–117
Esterbauer H, Cheeseman KH (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 186:407–421
Fontella FU, Gassen E, Pulrolnik V, Wannmacher CMD, Klein AB, Wajner M, Dutra CS (2002) Stimulation of lipid peroxidation in vitro in rat brain by metabolites accumulating in maple syrup urine disease. Metab Brain Dis 17:47–54
Gornall AG, Bardawill CJ, David MM (1949) Determination of serum proteins by means of the biuret reaction. J Biol Chem 177:751–766
Halliwell B (1994) Free radicals, antioxidants and human disease: curiosity, cause or consequence? Lancet 344:721–724
Halliwell B, Gutteridge JMC (eds) (2001) Free radicals in biology and medicine. Oxford University Press, Oxford
Joseph MH, Marsden CA (1986) Amino acids and small peptides. In: Lim CF (ed) HPLC of small peptides. IRL Press, Oxford, pp 13–27
Jouvet P, Rustin P, Taylor DL, Pocock JM, Felderhoff-Mueser U, Mazarakis ND, Sarraf C, Joashi U, Koszma M, Greewood K, Edwards AD, Mehmet H (2000) Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane despolarization or cytochrome c release: implications for neurological impairment associated with maple syrup urine disease. Mol Biol Cell 11:1919–1932
Lissi E, Pascual C, Del Castillo MD (1992) Luminol luminescence induced by 2,2′-azo-bis-(2-amidinopropane) thermolysis. Free Radic Res Commun 17:299–311
Lissi E, Salim-Hanna M, Pascual C, Del Castillo MD (1995) Evaluation of total antioxidant potential (TRAP) and total antioxidant reactivity from luminol-enhanced chemiluminescence measurements. Free Radic Biol Med 18:153–158
Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A (1993) A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 84:407–412
Pilla C, de Oliveira Cardozo RF, Dutra-Filho CS, Wyze ATS, Wajner M, Wannmacher CMD (2003) Effect of leucine administration on creatine kinase activity in rat brain. Metab Brain Dis 18:17–25
Przedborski S, Donaldson DBS, Jakowec M, Kish JS, Guttman M, Rosoklija G, Hays AP (1996) Brain superoxide dismutase, catalase and glutathione peroxidase activities in amyotrophic lateral sclerosis. Ann Neurol 39:158–165
Reznick AZ, Packer L (1993) Free radicals and antioxidants in muscular neurological diseases and disorders. In: Poli G, Albano E, Dianzani MU (eds) Free radicals: from basic science to medicine. Birkhäuser Verlag, Basel, pp 425–437
Schadewaldt P, Wendel U (1997) Metabolism of branched-chain amino acids in maple syrup urine disease. Eur J Pediatr 156(suppl. 1):S62–S66
Schönberger S, Schweiger B, Schwahn B, Schwarz M, Wendel U (2004) Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Mol Genet Metab 82:69–75
Sgaravatti AM, Rosa RB, Schuck PF, Ribeiro CAJ, Wannmacher CMD, Wyse ATS, Dutra-Filho CS, Wajner M (2003) Inhibition of brain energy metabolism by the α-keto acids accumulating in maple syrup urine disease. Biochim Biophys Acta 1639:232–238
Sirtori LR, Dutra-Filho CS, Fitarelli D, Sitta A, Haeser A, Barschak AG, Wajner M, Coelho DM, Llesuy S, Belló-Klein A, Giugliani R, Deon M, Vargas CR (2005) Oxidative stress in patient with phenylketonuria. Biochim Biophys Acta 1740:68–73
Snyderman SE, Norton PM, Roitman E, Holt LE Jr (1964) Maple syrup urine disease with particular reference to dietotherapy. Pediatrics 34:454–472
Taketomi T, Kunishita T, Hara A, Mizushima S (1983) Abnormal protein and lipid compositions of the cerebral myelin in patient with maple syrup urine disease. Jpn J Exp Med 53:109–116
Tavares RG, Santos CE, Tasca CI, Wajner M, Souza DO, Dutra-Filho CS (2000) Inhibition of glutamate uptake into synaptic vesicles of rat brain by the metabolites accumulating in maple syrup urine disease. J Neurol Sci 181:44–49
Treacy E, Clow CL, Reade TR, Chitayat D, Mamer OA, Scriver CR (1992) Maple syrup urine disease: interrelationship between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination. J Inherit Metab Dis 15:121–135
Tribble D, Shapira R (1983) Myelin proteins: degradation in rat brain initiated by metabolites causative of maple syrup urine disease. Biochem Biophys Res Commun 114:440–446
Vargas CR, Wajner M, Sirtori LR, Goulart L, Chiochetta M, Coelho D, Latini A, Llesuy S, Belló-Klein A, Giugliani R, Deon M, Mello CF (2004) Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim Biophys Acta 1688:26–32
Wajner M, Coelho DM, Barschak AG, Araujo PR, Pires RF, Lulhier FL, Vargas CR (2000) Reduction of large neutral amino acid concentrations in plasma and CSF of patients with maple syrup urine disease during crises. J Inherit Metab Dis 23:505–512
Wajner M, Latini A, Wyse ATS, Dutra-Filho CS (2004) The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J Inherit Metab Dis 27:427–448
Yu TW, Ong CN (1999) Lag-time measurement of antioxidant capacity using myoglobin and 2,29-azino-bis(3-ethyl-benzthiazoline-6-sulfonic acid): rationale, application and limitation. Anal Biochem 275:217–223
Zielke HR, Huang Y, Tildon JT, Zielke CL, Baab PJ (1996) Elevation of amino acids in the interstitial space of the rat brain following infusion of large neutral amino and keto acids by microdialysis: leucine infusion. Dev Neurosci 18:420–425
Acknowledgements
This work was supported by grants from Brazilian National Research Council (CNPq), CAPES, FAPERGS, and FIPE/HCPA—Brazil.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barschak, A.G., Sitta, A., Deon, M. et al. Oxidative stress in plasma from maple syrup urine disease patients during treatment. Metab Brain Dis 23, 71–80 (2008). https://doi.org/10.1007/s11011-007-9077-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-007-9077-y